Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jane Huang Insider Profile
4 Followers
Jane Huang, CMO, Hematology at BeiGene, holds 160.06K shares in BeiGene (Ticker: BGNE), holds ― shares in Protara Therapeutics (Ticker: TARA), holds 63.34K shares in Prelude Therapeutics (Ticker: PRLD).
Profitable Transactions
4 out of 7 Profitable Transactions
Average Return
+4.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jane Huang holds in companies
Most Profitable Insider Trade
The most profitable trade made by Jane Huang
Jane Huang's Trading History
BeiGene
Dec 16, 2021
CMO, Hematology
Uninformative Buy
179.94K
$30.46M
Protara Therapeutics
―
Director
―
―
Prelude Therapeutics
Oct 07, 2024
President, CMO
Uninformative Buy
12.05K
$61.06K
List of latest transactions for each holding click on a transaction to see Jane Huang's performance on stock
You May Also Like
Jane Huang insider profile FAQ
What is the percentage of profitable transactions made by Jane Huang?
The percentage of profitable transactions made by Jane Huang is 57%.
What is the average return per transaction made by Jane Huang?
The average return per transaction made by Jane Huang is 4.10%.
What stocks does Jane Huang hold?
Jane Huang holds: BGNE, TARA, PRLD stocks.
What was Jane Huang’s latest transaction?
Jane Huang latest transaction was an Uninformative Buy of $179.94K.
What was Jane Huang's most profitable transaction?
Jane Huang’s most profitable transaction was an Informative Sell of BGNE stock on June 9, 2021. The return on the trade was 56.60%.
What is Jane Huang's role in BeiGene?
Jane Huang's role in BeiGene is CMO, Hematology.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.